More about Huxley

   . . . of his creation -- the miracle, moment by moment of naked existence." In a letter to Chatto & Windus just after this mescaline experience, Huxley writes: "It is without any question the most extraordinary and significant experience available to human beings this side of the Beatific Vision; and it opens up a host of philosophical problems, throws intense light and raises all manner of questions in the fields of aesthetics, religion, theory of knowledge."

More about PIHKAL
  If it seems that there's something going on here, Sasha recommends it to his wife, hoping to get her reaction. Once she has concluded that the molecule in question may be an excellent candidate for being "loved," eleven associates who have been with this master chemist for a score of years all take it together with the Shulgins.
   The story told in these pages was originally sparked by a 1960 mescaline trip that quite astonished Sasha. His description of that odyssey appears both here and in his "Twenty Years on a Never-Ending Quest" in Grinspoon and Bakalar's
Psychedelic Reflections. In a nutshell, Sasha was knocked out by the realization that the simple mescaline molecule wasn't the source of his dramatically-enhanced consciousness, but it had nonetheless given him an "access code" to complex thoughts that were already in his mind.
   Shulgin, who normally shuns public appearances, electrified a psychedelic conference at the university near Santa Barbara in the early '80s when he explained, at his wife's insistence, "What I Do and Why I Do It," coming close to tears at the end. He spoke then about the classic battle between life and death forces ("eros" and "thanatos," in more classical terms), and asserted that in this fight he would do as much as he could "as quickly as possible."
   Although most of the second half of the book, synthesis routes,
et al., may be largely unreadable to those untrained or uninterested in the vocabulary of chemistry, its distribution undoubtedly sets this volume widely apart from ordinary kinds of writing with thanks, no doubt, to present and future alchemists.
   Shulgin's first important intervention had to do with his synthesis of a molecule called "DOM," which had been new to him and which eventually showed up a few years later as "STP." Now recalled in horror, or favor and gratitude in smaller circles, this compound some 200 times more powerful by weight than mescaline played a prominent role in psychedelic history, as 5,000 very powerful doses were distributed at the first Human Be-In in mid-'60s San Francisco.

  Over the next decade, there were to be nine other tries -- two more with mescaline, one with morning glory seeds (eight of them), two with psilocybin and four with LSD. This may not be considered by some that much experience. But Huxley and his colleagues -- mainly Osmond -- were unusually sensitive to and articulate about what was at stake here. In an important sense, they have affected the way in which we see the issues.
   In the first of his two short books about psychedelics --
The Doors of Perception -- Huxley remarked that the "untalented visionary may perceive an inner reality no less tremendous, beautiful and significant than the world beheld by Blake; but he lacks altogether the ability to express, in literary or plastic symbols, what he has seen."
  Unfortunately, instead of the 2-4 mg. dosage Shulgin originally recommended, the stuff was given out in 15 mg. tablets. Effects of this particular psychedelic come on in wave-like fashion (much like thinking you're at the top of a mountain while hiking, only to find that it's but the top of a ridge, and that another "mountain top" now is visible). Intensity and duration here are closely dose-related.
   In the Be-In case, many swallowers went on a three-day, wild odyssey that they hadn't anticipated, thus making sense of the idea that "This psychedelic thing might go too far," or at least further than some wanted to go.
  Another Shulgin contribution of great import to the history of psychedelics came along as a result of publication of his first article about MDMA, co-authored with an important colleague, psychopharmacologist David Nichols of Purdue University. This substance -- also known as "Ecstasy" and "M&Ms," among other names -- was originally patented by the Mercke firm in Germany in 1914. It's not clear yet that it was ever tried
                         (more to come
)
  Aldous, by way of contrast, by the time of his first contrived mystical experience had already spent a long lifetime as a student of the curious and mystical, and of English prose. Writing first about psychedelics at the age of 60, he was able to give
             (continued)
Back to
Contents Page
Hosted by www.Geocities.ws

1